PillPack (Amazon Pharmacy) vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Amazon's pharmacy combining PillPack multi-medication pre-sorting with Prime prescription delivery; disrupting CVS and Walgreens with price transparency and same-day delivery in growing cities.
About
PillPack (now Amazon Pharmacy) is Amazon's full-service online pharmacy providing prescription delivery, medication management, and pharmacy services to US customers — originally founded as PillPack in 2013 by TJ Parker and Elliott Cohen to solve medication adherence for patients on multiple prescriptions, then acquired by Amazon in 2018 for $1 billion. Amazon has since rebranded the full-service pharmacy to Amazon Pharmacy while maintaining the PillPack brand for the multi-medication pre-sorting service for customers taking 5+ daily medications.\n\nPillPack's distinctive original service pre-sorts medications by dose and time (individual packets labeled "Monday 8AM: Take these 3 pills"), eliminating the confusion of managing multiple prescription bottles for patients with complex medication regimens. This packaging format particularly serves elderly patients and chronic disease patients taking 5-15 medications daily. Amazon Pharmacy (the broader service) provides standard prescription delivery with Prime shipping, price transparency through Amazon's prescription discount program, and pharmacist consultations.\n\nIn 2025, Amazon Pharmacy operates as a significant disruptor in the $350 billion US prescription market, competing with CVS Health (the largest pharmacy chain), Walgreens, Express Scripts (mail-order PBM pharmacy), and new pharmacy entrants like Ro, Alto Pharmacy, and Capsule. Amazon's advantages are its logistics infrastructure (Prime 2-day/same-day delivery), price comparison transparency, and consumer trust for e-commerce transactions. The 2025 strategy focuses on expanding same-day prescription delivery in more cities, growing specialty pharmacy capabilities for high-cost biologic medications, and integrating pharmacy with Amazon's broader health ecosystem (One Medical primary care, Amazon HealthLake health records).
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.